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Each month, Chemistry & Biology Select highlights a selection of research reports from the recent
literature. These highlights are a snapshot of interesting research done across the field of chemical
biology. Our September 2015 selection includes a way to indulge cancer cell oncogene addiction
and push cancer cells to self-destroy; a tin-containing, small-molecule tool compound that targets
an intrinsically disordered region of eukaryotic transcription factor TFIID; and evidence that bacte-
ria produce antibiotics for one purpose only—as deadly weapons.Tin is a versatile metal, with numerous uses
including, perhaps most famously, for making
tin cans. Zhang et al. describe a very
unexpected discovery that tin(IV) oxochloride is
an inhibitor of eukaryotic general transcription
factor TFIID, and moreover that it binds a region
of TFIID that is known to be intrinsically
disordered. Image credit: M. Kostic.A Tintalizing Discovery
Intrinsically disordered proteins (IDPs), also known as intrinsically disordered
regions (IDRs), are regions of a protein sequence that don’t fold into a well-
defined structure on their own. Despite the lack of intrinsic structure, they are
functionally important, as illustrated by the fact that they are overrepresented
in signaling pathways and that the more complex an organism is, the more
IDR/Ps it has. IDRs usually occur in the context of large proteins that have
multiple, functionally distinct domains. Eukaryotic general transcription factor
TFIID is a complex formed by the TATA-binding protein (TBP) and approxi-
mately 14 TBP-associated factors (TAFs), and the TAF2 subunit harbors an IDR.
Zhang et al. screened a library of approximately 10,000 organic compounds
for TFIID binding and identified a hit that inhibited TFIID in the context of hu-
man reconstituted cell-free transcription system. To their dismay, the authors
observed that the lead compound resynthesized in the lab completely lost the
inhibitory activity. This led them to reanalyze the commercially available com-
pounds. What they discovered is quite interesting: the activity is due not to
the compound, but to a tin(IV) oxochloride cluster that is a contamination
left over from the crystallization conditions used. In this paper, Zhang et al.
proceeded to show that the tin-complex inhibits TFIID by binding to an IDR
of TAF2, and that this binding depends on the presence of DNA, which is
believed to help stabilize a transient TAF2 IDR conformation competent to
bind the tin compound. Tin(IV) oxochloride binding locks TFIID-DNA complex
into a conformation that can’t engage Pol II during de novo transcription pre-
initiation complex (PIC) formation. On the other hand, Zhang et al. show that
re-entry of Pol II during reinitiation apparently takes a bypass pathway
because it’s resistant to the inhibition. This means that tin(IV) oxochloride is an interesting mechanistic tool to study tran-
scription, as it allows one to separate de novo transcription from reinitiation.
Apart from providing an insight into mechanism of transcription and TFIID function, this work is tantalizing in a couple of
different ways: first, it suggests TFIID may be a drug target, and second, it points to an unconventional potential strategy
for targeting IDP/Rswhich are generally considered undruggable. The work is also a cautionary tale reminding everyone using
small-molecule tools about the importance of thoroughly checking the purity and structure of the tool compound before
use since some biologically active inorganic material introduced during synthesis may escape detection by standard organic
analysis.
Zhang et al. (2015) eLife. Published August 28, 2015. http://dx.doi.org/10.7554/eLife.07777Too Much of a Good Thing
Members of the p160 steroid receptor coactivator (SRC) family, SRC-1, SRC-2, and SRC-3, orchestrate a wide range of
cellular functions not limited to coactivation of steroid hormone receptor-mediated gene transcription, but also to the regu-
lation of energy homeostasis, RNA splicing, and protein synthesis. This means that SRCs don’t bind only the hormone recep-
tors; they actually have a long, and growing, list of interaction partners and spend most of the time as a part of multiprotein
complexes deployed to perform different cellular tasks.Chemistry & Biology 22, September 17, 2015 ª2015 Elsevier Ltd All rights reserved 1157
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tasis, and SRCs are therefore considered to be oncogenes. As such, finding ways to inhibit their ability to engage in protein-
protein interactions that are important for supporting tumorigenesis ormetastasis is of interest. Surprisingly, Wang et al. found
that the stimulation of SRCs is also a viable strategy for killing cancer cells. In a new report, Wang et al. describe the discovery
of MCB-613, a small-molecule stimulator (SMS) of SRCs. MCB-613 interacts directly with SRC-3 by binding the coactivator’s
receptor-interacting domain (RID). MCB-613 subsequently promotes coactivator complex formation and increases transcrip-
tional activity, eventually resulting in cancer cell death, through a type of programmed cell death known as paraptosis. MCB-
613 activates SRCs beyond the levels that cancer cells utilize for maintaining their physiology. This causes ER stress and the
unfolded protein response (UPR) pathways that are already maximally engaged in cancer cells to run out of control, resulting
in increased levels of reactive oxygen species (ROS). The culmination of all these changes is the selective death of cancer
cells. The work highlights the need for drug discovery and development programs to consider exploring not only the inhibition
of oncogenes but their activation as well as.
Wang et al. (2015). Cancer Cell 28:240–252. http://dx.doi.org/10.1016/j.ccell.2015.07.005Despite some recent suggestions that bacteria
might use antibiotics for mediating
cooperation, in addition to their recognized role
as bacterial weapons, this is not born out by
evidence presented by Abrudan et al., who
show that Streptomyces strains use antibiotics
to fight each other. Image source: ‘‘Battle of
Issus’’ by Albrecht Altdorfer ‘‘Battle of Issus’’
(public domain via Wikimedia Commons).
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The most puzzling thing about antibiotics is that it is bacteria, the very organ-
isms they kill, that produce them. Antibiotics are complex molecules, often
made at a great metabolic expense for the producer. Therefore, it is hard to
imagine that bacteria evolved to make antibiotics for the benefit of humanity,
in order to equip us with ways to fight against them. One more realistic possi-
bility is that bacteria produce antibiotics asweapons against competitors. Alter-
natively, they might be using these molecules for intra- and interspecies
communication or as signals in complex microbial communities.
Abrudan et al. put these possibilities to the test in order to determine the role
of antibiotics in nature. They use bacterial strains from Streptomyces because
streptomycetes are well-known antibiotic production powerhouses, with close
to 70% of all antibiotics in clinical use having originated from a Streptomyces
producer. Abrudan et al. expose different strains to a range of growth condi-
tions in the absence or presence of other strains, with the idea of testing the
impact of asocial and social growth conditions on antibiotic production. What
they see is that strains do not hold back punches and that they not only ramp
up their own antibiotic production, but, at the same time, employ strategies
to decrease antibiotic production of their competitors. This leads to interesting
social dynamics in a complex microbial community that depends on the
resource availability and identity of neighbors. Although many questions about
the evolution and ecology of antibiotic production remain, Abrudan et al. arguethat their study does not support the view of antibiotics as a language of cooperation.
Abrudan et al. (2015). Proc. Natl. Acad. Sci. USA. 112:11054–11059. http://dx.doi.org/10.1073/pnas.1504076112
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